- Home
- INVA vs TRVI Comparison
INVA vs TRVI Comparison
Compare INVA & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INVA | TRVI |
|---|---|---|
| Founded | 1996 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | 2004 | 2019 |
Fundamental Metrics
Financial Performance| Metric | INVA | TRVI |
|---|---|---|
| Price | $19.64 | $11.24 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 12 |
| Target Price | ★ $36.80 | $20.38 |
| AVG Volume (30 Days) | 940.8K | ★ 1.9M |
| Earning Date | 02-25-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 53.96 | N/A |
| EPS | ★ 1.52 | N/A |
| Revenue | ★ $388,521,000.00 | N/A |
| Revenue This Year | $13.23 | N/A |
| Revenue Next Year | $8.58 | N/A |
| P/E Ratio | $12.81 | ★ N/A |
| Revenue Growth | ★ 10.14 | N/A |
| 52 Week Low | $16.52 | $3.47 |
| 52 Week High | $22.76 | $14.39 |
Technical Indicators
Market Signals| Indicator | INVA | TRVI |
|---|---|---|
| Relative Strength Index (RSI) | 44.35 | 39.04 |
| Support Level | $19.26 | $10.58 |
| Resistance Level | $20.23 | $13.16 |
| Average True Range (ATR) | 0.46 | 0.67 |
| MACD | -0.04 | -0.22 |
| Stochastic Oscillator | 45.54 | 26.89 |
Price Performance
Historical ComparisonAbout INVA Innoviva Inc.
Innoviva Inc is a company with a portfolio of royalties healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.